ReviewInternational journal of clinical oncology2026
Microflora: a promising potential in the diagnosis and treatment of non-small cell lung cancer.
Review in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The incidence and mortality of non-small cell lung cancer (NSCLC) remain high in China. Recently, several studies have shown a complex correlation between microflora and NSCLC. Compared to patients with healthy/benign lung disease, patients with NSCLC have distinct microflora within the tumor, airways as well as intestines. NSCLC can be diagnosed with the assistance of characteristic microflora and circulating microbial DNA. Microflora changes can affect the efficacy of immunotherapy and treatment-related adverse effects during lung cancer therapy. Modulating microflora imbalance through antibiotics/probiotics nebulization, oral probiotic, prebiotics, and dietary modifications can balance microflora and enhance the effectiveness of immunotherapy. Therefore, microbe-specific testing and targeted therapy have the potential to become a new method in the diagnosis and treatment of NSCLC. This review will explore the molecular mechanisms by which microbes influence lung cancer, and summarize the latest research advances in microbial biomarkers and therapeutic approaches for NSCLC.
Indexed as
Identifiers
41388199What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.